Login to Your Account

31st Annual J.P. Morgan Healthcare Conference

Who's 'Afrezza' the FDA? Not MannKind, Still Plugging Away

By Randy Osborne
Staff Writer

Friday, January 11, 2013
As FDA-mandated Phase III trials near their finish with MannKind Corp.'s beleaguered inhaled insulin product Afrezza, Alfred Mann, CEO and major funder of the company, took to the lectern at the J.P. Morgan Healthcare Conference to deliver a familiar message: It works, the device is simple and patients will use it.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription